Breaking the Biomarker Bottlenecks: Part 1

Top Institutions in Precision Medicine and Companion Diagnostics in Oncology

Institutions leading in this area typically combine cutting-edge molecular pathology, computational biology, and AI-driven diagnostic technologies with robust clinical trial programs and industry collaborations to advance companion diagnostic development and implementation.

#1

Memorial Sloan Kettering Cancer Center

New York, NY
MSKCC is a global leader in precision oncology, with extensive programs in molecular diagnostics and companion diagnostic development integrated into clinical care and trials. Their research in computational pathology and AI applications in cancer diagnostics is highly influential.
Key Differentiators
- Precision Medicine
- Oncology
- Molecular Pathology
- Computational Biology
#2

Dana-Farber Cancer Institute

Boston, MA
Dana-Farber integrates translational research with clinical oncology, focusing on biomarker-driven therapies and companion diagnostics. Their leadership in clinical trials and biomarker discovery supports precision medicine advancements.
Key Differentiators
- Oncology
- Precision Medicine
- Molecular Diagnostics
#3

MD Anderson Cancer Center

Houston, TX
MD Anderson is renowned for its comprehensive cancer genomics programs and integration of molecular diagnostics into patient care, including companion diagnostics to optimize treatment selection.
Key Differentiators
- Cancer Genomics
- Precision Medicine
- Pathology
#4

Broad Institute of MIT and Harvard

Cambridge, MA
The Broad Institute excels in large-scale genomic and computational biology research, driving biomarker discovery and development of companion diagnostics through innovative AI and machine learning approaches.
Key Differentiators
- Genomics
- Computational Biology
- Precision Medicine
#5

Stanford University School of Medicine

Stanford, CA
Stanford combines expertise in molecular diagnostics and AI to develop next-generation companion diagnostics, with a focus on integrating computational pathology into clinical workflows.
Key Differentiators
- Precision Oncology
- Molecular Diagnostics
- Artificial Intelligence

References

M Takeda et al., "Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors," Oncologist, 24, 4 (2021). PMID: 33325566.
VA Ionescu, et al., "Clinical, immunohistochemical, and inflammatory profiles in colorectal cancer: the impact of MMR deficiency," Diagnostics (Basel), 15, 17 (2025). PMID:40941629.

Breaking the Biomarker Bottlenecks: Part 1

When pharmaceutical and diagnostic companies collaborate, precision medicine reaches patients faster, say these industry leaders

Top Institutions in Precision Medicine and Companion Diagnostics in Oncology

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

MD Anderson Cancer Center

Broad Institute of MIT and Harvard

Stanford University School of Medicine

References

Explore More in Pathology

Recommended

A Helping Hand from AI in Prostate Cancer Diagnostics

The Ultimate Vision for Rare Disease

A Light in the Darkness

In-House Matters

Explore

Featured Topics

Issues

Career Development

Educational Resources

Events

People & Profiles

Breaking the Biomarker Bottlenecks: Part 1

When pharmaceutical and diagnostic companies collaborate, precision medicine reaches patients faster, say these industry leaders

Top Institutions in Precision Medicine and Companion Diagnostics in Oncology

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

MD Anderson Cancer Center

Broad Institute of MIT and Harvard

Stanford University School of Medicine

Newsletters

References

Explore More in Pathology

Recommended

Related Content

A Helping Hand from AI in Prostate Cancer Diagnostics

The Ultimate Vision for Rare Disease

A Light in the Darkness

In-House Matters